Prognostic significance of mutations in theKITgene in CBF AML patients.
| Chromosome Aberration . | Age, Range (Median) Years . | No. Patients . | Total . | Exon 8 . | Exon 17 . | Other . | Prognostic Significance . | Ref. . |
|---|---|---|---|---|---|---|---|---|
| Abbreviations: KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; pts, patients; OS, overall survival; RI, relapse incidence; EFS, event-free survival; RFS, relapse-free survival; CIR, cumulative incidence of relapse; RR, relapse rate; NA, not analyzed; NR, not reported. | ||||||||
| * Numbers of patients for whom clinical data were available. | ||||||||
| † Median age and range of all 1940 patients analyzed for KIT mutations. | ||||||||
| ‡ Age range and median provided for all patients with CBF AML, including 56 with t(8;21) and 47 with inv(16)/t(16;16). | ||||||||
| § Mean age. | ||||||||
| || One patient with inv(16) whose clinical outcome was analyzed had a non-exon 17 mutation, but it is unclear if this was an exon 8 or other KIT mutation. | ||||||||
| t(8;21) | 16–76 (40.5) | 36 | 17 (47%) | 5 (14%) | 12 (33%) | 2 (6%) | OS: Significantly shorter for pts with any KIT mutation (24 mo OS rates: 42% vs 77%, P = 0.017) and for pts with exon 17 mutation (24 mo OS rates: 25% vs 77%, P = 0.006) compared with pts without KIT mutations. | 42 |
| 34 | 15 (44%) | 5 (15%) | 10 (29%) | 2 (6%) | RI: Significantly higher for pts with any KIT mutation (24 mo RI rates: 77% vs 35%, P = 0.005) and for pts with exon 17 mutation (24 mo OS rates: 90% vs 35%, P = 0.002) compared with pts without KIT mutations. | |||
| t(8;21) | 15–90 | 64 | 8 (13%) | NA | 8 (13%) | NA | OS: Significantly shorter for pts with exon 17 KIT mutation (median: 304 d vs 1836 d, P < 0.001). EFS: Significantly shorter for pts with exon 17 KIT mutation (median: 244 d vs 744 d, P = 0.003). | 43 |
| t(8;21) | 1–75 (33)‡ | 50 | 6 (12%) | 3 (6%) | 3 (6%) | NA | OS: Significantly shorter for pts with any KIT mutation ( P = 0.03). EFS: Significantly shorter for pts with any KIT mutation ( P = 0.006). RFS: Significantly shorter for pts with any KIT mutation ( P = 0.005). | 44 |
| t(8;21) | 18–71 (37) | 49 | 11 (22%) | 2 (4%) | 9 (18%) | NA | OS: No significant difference between pts with or without KIT mutations. CIR: Significantly higher for patients with any KIT mutation (5-year CIR 70% vs 36%, P = 0.017) compared with those without KIT mutations. | 45 |
| inv(16) | 15–74 (44)§ | 63 | 20 (32%) | 15 (24%) | 5 (8%) | NA | OS: No significant difference between pts with and without exon 8 mutations. Mutations in exon 17 not analyzed. RR: Significantly higher for pts with exon 8 mutations compared with pts without exon 8 mutations. Mutations in exon 17 not analyzed. | 46 |
| inv(16)/ t(16;16) | 17–88 (51) | 17 | 8 (47%) | NR|| | 7 (41%) | NR|| | OS: No significant differences between pts with any KIT mutation or with exon 17 mutation and those without KIT mutations. RI: No significant difference between pts with any KIT mutation or with exon 17 mutation and those without KIT mutations. | 42 |
| inv(16)/ (16;16) | 1–75 (33)‡ | 46 | 10 (22%) | 9 (20%) | 1 (2%) | NA | OS: No significant difference between pts with any KIT mutation and those without KIT mutations. | 44 |
| inv(16)/ t(16;16) | 19–57 (40) | 61 | 18 (30%) | 8 (13%) | 10 (16%) | NA | OS: No significant differences between pts without KIT mutations and those with any KIT mutation, with exon 17 mutation and exon 8 sole mutation. In multivariable analyses, any KIT mutation predicted worse overall survival (OS) after adjusting for sex. CIR: Significantly higher for patients with any KIT mutation (5-year CIR 56% vs 29%, P = 0.05) and pts with exon 17 mutation (5-year CIR 80% vs 29%, P = 0.002) compared with those without KIT mutations. No significant difference between pts with exon 8 sole mutation and those without KIT mutations. | 45 |
| Chromosome Aberration . | Age, Range (Median) Years . | No. Patients . | Total . | Exon 8 . | Exon 17 . | Other . | Prognostic Significance . | Ref. . |
|---|---|---|---|---|---|---|---|---|
| Abbreviations: KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; pts, patients; OS, overall survival; RI, relapse incidence; EFS, event-free survival; RFS, relapse-free survival; CIR, cumulative incidence of relapse; RR, relapse rate; NA, not analyzed; NR, not reported. | ||||||||
| * Numbers of patients for whom clinical data were available. | ||||||||
| † Median age and range of all 1940 patients analyzed for KIT mutations. | ||||||||
| ‡ Age range and median provided for all patients with CBF AML, including 56 with t(8;21) and 47 with inv(16)/t(16;16). | ||||||||
| § Mean age. | ||||||||
| || One patient with inv(16) whose clinical outcome was analyzed had a non-exon 17 mutation, but it is unclear if this was an exon 8 or other KIT mutation. | ||||||||
| t(8;21) | 16–76 (40.5) | 36 | 17 (47%) | 5 (14%) | 12 (33%) | 2 (6%) | OS: Significantly shorter for pts with any KIT mutation (24 mo OS rates: 42% vs 77%, P = 0.017) and for pts with exon 17 mutation (24 mo OS rates: 25% vs 77%, P = 0.006) compared with pts without KIT mutations. | 42 |
| 34 | 15 (44%) | 5 (15%) | 10 (29%) | 2 (6%) | RI: Significantly higher for pts with any KIT mutation (24 mo RI rates: 77% vs 35%, P = 0.005) and for pts with exon 17 mutation (24 mo OS rates: 90% vs 35%, P = 0.002) compared with pts without KIT mutations. | |||
| t(8;21) | 15–90 | 64 | 8 (13%) | NA | 8 (13%) | NA | OS: Significantly shorter for pts with exon 17 KIT mutation (median: 304 d vs 1836 d, P < 0.001). EFS: Significantly shorter for pts with exon 17 KIT mutation (median: 244 d vs 744 d, P = 0.003). | 43 |
| t(8;21) | 1–75 (33)‡ | 50 | 6 (12%) | 3 (6%) | 3 (6%) | NA | OS: Significantly shorter for pts with any KIT mutation ( P = 0.03). EFS: Significantly shorter for pts with any KIT mutation ( P = 0.006). RFS: Significantly shorter for pts with any KIT mutation ( P = 0.005). | 44 |
| t(8;21) | 18–71 (37) | 49 | 11 (22%) | 2 (4%) | 9 (18%) | NA | OS: No significant difference between pts with or without KIT mutations. CIR: Significantly higher for patients with any KIT mutation (5-year CIR 70% vs 36%, P = 0.017) compared with those without KIT mutations. | 45 |
| inv(16) | 15–74 (44)§ | 63 | 20 (32%) | 15 (24%) | 5 (8%) | NA | OS: No significant difference between pts with and without exon 8 mutations. Mutations in exon 17 not analyzed. RR: Significantly higher for pts with exon 8 mutations compared with pts without exon 8 mutations. Mutations in exon 17 not analyzed. | 46 |
| inv(16)/ t(16;16) | 17–88 (51) | 17 | 8 (47%) | NR|| | 7 (41%) | NR|| | OS: No significant differences between pts with any KIT mutation or with exon 17 mutation and those without KIT mutations. RI: No significant difference between pts with any KIT mutation or with exon 17 mutation and those without KIT mutations. | 42 |
| inv(16)/ (16;16) | 1–75 (33)‡ | 46 | 10 (22%) | 9 (20%) | 1 (2%) | NA | OS: No significant difference between pts with any KIT mutation and those without KIT mutations. | 44 |
| inv(16)/ t(16;16) | 19–57 (40) | 61 | 18 (30%) | 8 (13%) | 10 (16%) | NA | OS: No significant differences between pts without KIT mutations and those with any KIT mutation, with exon 17 mutation and exon 8 sole mutation. In multivariable analyses, any KIT mutation predicted worse overall survival (OS) after adjusting for sex. CIR: Significantly higher for patients with any KIT mutation (5-year CIR 56% vs 29%, P = 0.05) and pts with exon 17 mutation (5-year CIR 80% vs 29%, P = 0.002) compared with those without KIT mutations. No significant difference between pts with exon 8 sole mutation and those without KIT mutations. | 45 |